Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. - Wikidata - awgldk - TriplyDB

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

http://www.wikidata.org/entity/Q45385574

about

Interferon alpha for chronic hepatitis B KASL clinical practice guidelines: management of chronic hepatitis B Current and future directions for treating hepatitis B virus infection Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Direct acting antivirals for the treatment of chronic viral hepatitis New virologic tools for management of chronic hepatitis B and C Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Recent advances in understanding and diagnosing hepatitis B virus infection Immune-Regulatory Events in the Clearance of HBsAg in Chronic Hepatitis B: Focuses on HLA-DP Current hepatitis B treatment guidelines and future research directions.HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.Alpha-interferon treatment in hepatitis B Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.Quantitative measurement of serum hepatitis B surface antigen using an immunoradiometric assay in chronic hepatitis B Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Long-term therapy of chronic delta hepatitis with peginterferon alfa.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.The Role of Interferon in Hepatitis B Therapy.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.Antiviral treatment of chronic hepatitis B virus (HBV) infections Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study Evaluation of changes of serum hepatitis B surface antigen from a different perspective.Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV.Chronic hepatitis B: management challenges in resource-poor countries Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.

P2860

Q24235232-C101EDD9-D549-48BA-A73E-E813D0DD7E74 Q26752475-0ECE1C0D-F7F6-4D84-B717-47AD64429996 Q26851240-DAF15E9F-D10F-464F-9173-6068E40C2D9E Q27000080-78A10E05-DEE8-4F28-8E14-CE930BD13AFC Q27022216-F4787603-5ED1-4835-A915-0440EBA70CF1 Q27026914-6876FF49-5C22-4956-8123-AA877F51EC18 Q27030828-DC48982D-1EC3-4939-9B10-A67A9BB37862 Q28067419-B10569A0-1BDB-4732-9D85-3C8608D7E96E Q28086834-38873B4A-7C98-47E0-B818-2C0CC722863B Q30487002-A354747F-05FB-439E-84A6-6B21E44DF732 Q30741676-A3D313A7-E07F-4315-AEBD-161AD0DACC9E Q33592755-650C6D0D-49BE-4614-BB21-24A4C471ACA5 Q33637292-73AAA024-0129-4A29-AF73-9ED55B0E7DB9 Q33676594-CFB3887A-4CB9-405B-9B53-A35AF60055E8 Q33704165-6BA4ACFB-73F0-443D-94D7-1BD6A4A463C9 Q33734554-DD99787F-0EE6-48D5-A551-01A3EA0EF20D Q33819124-9D2C8E43-A6C0-4AD8-B206-E05862F5F7FA Q33845546-BA5ABCEB-3A5E-4C39-AFBA-4AD86131578E Q33904679-582A9128-8753-4F4D-87E9-ECA9943E9DC7 Q34137291-399CF8CC-1853-44C2-9608-44186454EF84 Q34154958-0BA00A79-A043-495F-A46F-E82B3D2E3637 Q34168465-082D9392-C41F-4BCC-912C-68F64CD5A2C6 Q34189348-B1A1410F-B0A0-44BF-A875-3E7D3A51AF4E Q34223779-051405B3-42B3-495F-BF94-627B28992990 Q34339613-BC0694D2-465E-49B7-B7F4-B20AE8C653EC Q34362568-6E5F468A-88A5-4139-8316-8E45A0FFB594 Q34384793-577C979B-B259-479B-94ED-C0F050D297BB Q34414722-079FCCC7-2F47-43C3-BF35-F4EC296DE28F Q34505113-EC1DC1E7-4082-40B2-98B5-5660ADFC523A Q34592952-343051CB-123D-4032-92A5-04860F5714EB Q34598267-30E9BF0E-1E2E-41B4-A649-99AA02CC4A42 Q34674838-90B76C45-FC8D-40E0-8D8A-3B2B586DEAAD Q35017075-046D8823-EC7C-4A63-A106-703C5585A40B Q35152364-5B905818-DA38-4972-BD7C-ADC6755BE0E0 Q35250340-F5B1B591-1C98-4295-840D-530EE61DB4B3 Q35402699-8D7F1E59-23CC-45B7-B06A-7E2F29D2F949 Q35487430-E9A0B73A-EC69-4D69-B823-C031FA0871F7 Q35540204-A29551AC-D67E-492A-ACC9-D414FC7E4AA3 Q35603813-464E9DBD-C17F-4544-A9BE-21EB14D204A2 Q35739079-EA0F94F1-20CB-4A68-9D53-60011BD75BE8

P2860

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

http://www.wikidata.org/entity/Q45385574

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@en

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@nl

type

label

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@en

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@nl

prefLabel

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@en

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@nl

P1433

Q45385574-8AFF3F7D-69AE-4324-802A-5AA91162A3BB

P1476

Q45385574-9EF4B170-CB79-4F93-B71E-64AAD0E051F8

P2093

Q45385574-18C31B36-39D3-485F-8E1A-5F3EF2322D67

Q45385574-232FDDA7-9B01-4FF2-95F1-BE5C19ABC33E

Q45385574-34D61E43-B2FB-4BA8-85FE-7F01C25B6228

Q45385574-47176197-AC9E-42CA-A7F3-B8E54368D30C

Q45385574-8455A742-6176-4E35-9D1C-291E3195C549

Q45385574-8E745A85-D34A-42AD-9CF5-27F51763F171

Q45385574-9519F887-78DE-427C-A20F-7AA1558D9BFC

Q45385574-99FB163B-846F-4C0C-BCD7-BC57910B4D95

Q45385574-C98EAAF8-8D46-4EBE-B5BC-E8F15586BA5F

Q45385574-D3482FC0-A0C9-4702-B596-A5464711403B

P2860

Q45385574-0C00493A-2448-49A4-A236-D1D407A28926

Q45385574-2A5CCC33-64CE-48B0-9F43-DE0857C38D6B

Q45385574-3613C452-D8E8-40E8-8D33-1082178C6B71

Q45385574-3C90BAAE-AE42-40A6-B8A0-3D8D89FAA538

Q45385574-624D6299-5FF7-47EA-9C31-37D2BEC071C9

Q45385574-7A4FED90-1203-4B77-BF1C-0DA355AF78EB

Q45385574-7AC5305A-FAF6-488D-9CC4-070F1632A75A

Q45385574-9263A123-9D26-43DD-8A2A-40652308A3B3

Q45385574-933B4139-BFFB-4A66-B873-3E6CCCB506FA

Q45385574-98DCBF1E-D9B5-4312-9392-744567D0FC57

P304

Q45385574-4A211E3D-86D9-4D86-B880-D48D068D9DEC

P31

Q45385574-440CA92C-A2E6-41BE-849A-C4778E954294

P356

Q45385574-22672171-3BC2-4677-80CB-40FFD4E8DE93

P407

Q45385574-C555AF81-D7CA-43F6-89D9-27DC2F7C07B4

P433

Q45385574-152300CB-FCDC-4001-AD03-12CB6F881D3B

P478

Q45385574-15F16B37-34D8-4473-AE13-7F9B06D66A4A

P50

Q45385574-0E9E390F-6208-46AC-9CF8-E5FD202A2F81

Q45385574-8DAAB69F-1ADC-4434-81F2-73C194595276

P577

Q45385574-DD5441ED-F06F-466E-A1BE-E585763E9824

P5875

Q45385574-D2E08C76-C14B-4057-A01D-35B3664C6DBE

P698

Q45385574-A0FC77AF-F529-4728-819B-2B5335CD8C52

P356

P1433

P1476

Hepatitis B virus surface anti ...... -negative chronic hepatitis B.

@en

P2093

Cihan Yurdaydin

http://www.w3.org/2001/XMLSchema#string

Eva Wolf

http://www.w3.org/2001/XMLSchema#string

Francesco Moriconi

http://www.w3.org/2001/XMLSchema#string

George K K Lau

http://www.w3.org/2001/XMLSchema#string

Kangxian Luo

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Patrizia Farci

http://www.w3.org/2001/XMLSchema#string

Philip McCloud

http://www.w3.org/2001/XMLSchema#string

Richard Batrla

http://www.w3.org/2001/XMLSchema#string

Stephanos Hadziyannis

http://www.w3.org/2001/XMLSchema#string

P2860

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Chronic hepatitis B.

Hepatitis B e antigen-negative chronic hepatitis B.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Current issues and future directions in treatment.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

P304

1141-1150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22760

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Ferruccio Bonino

Maurizia R Brunetto

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24249798

http://www.w3.org/2001/XMLSchema#string

P698

19338056

http://www.w3.org/2001/XMLSchema#string